Elicio Opts Out of EGC Accounting Transition Period
Ticker: ELTX · Form: 8-K · Filed: Jan 17, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Jan 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, accounting-standards, emerging-growth-company
TL;DR
**Elicio is adopting new accounting rules faster, signaling a move towards standard financial reporting.**
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on January 17, 2024, indicating it is an "emerging growth company" and has elected not to use the extended transition period for complying with new or revised accounting standards. This means the company will adopt new accounting rules at the same time as larger, non-emerging growth companies. For investors, this matters because it suggests Elicio is opting for more immediate compliance with financial reporting standards, potentially signaling a commitment to transparency and alignment with established companies, which could be viewed positively.
Why It Matters
This decision means Elicio Therapeutics will adopt new accounting standards sooner, potentially increasing transparency and aligning its financial reporting more quickly with larger, established companies.
Risk Assessment
Risk Level: low — This filing is purely administrative, indicating a choice regarding accounting standards, and does not present immediate financial risk.
Analyst Insight
Investors should note this administrative decision as it indicates Elicio's approach to financial reporting, aligning with more mature companies, which could be a positive signal for governance and transparency.
Key Numbers
- $0.01 — par value per share (par value of Elicio Therapeutics' common stock)
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 17, 2024 (date) — date of earliest event reported and filing date
- The Nasdaq Global Select Market (company) — exchange where Elicio's common stock is registered
- $0.01 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- Elicio Therapeutics will continue to prioritize timely adoption of new accounting standards. (Elicio Therapeutics, Inc.) — high confidence, target: ongoing
FAQ
What is the primary purpose of this 8-K filing by Elicio Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report that Elicio Therapeutics, Inc. is an "emerging growth company" and has elected not to use the extended transition period for complying with any new or revised financial accounting standards, as indicated by the checked box on the form.
What does it mean for Elicio Therapeutics to be an 'emerging growth company'?
As an 'emerging growth company,' Elicio Therapeutics, Inc. is subject to certain scaled disclosure requirements and exemptions under the Securities Act of 1933 and the Securities Exchange Act of 1934, as defined in Rule 405 and Rule 12b-2, respectively.
What is the significance of Elicio Therapeutics electing 'not to use the extended transition period'?
By electing not to use the extended transition period, Elicio Therapeutics, Inc. will adopt new or revised financial accounting standards at the same time as public companies that are not emerging growth companies, rather than taking advantage of a delayed adoption period available to EGCs.
On what date was this 8-K filed and what was the date of the earliest event reported?
The 8-K was filed on January 17, 2024, and the date of the earliest event reported was also January 17, 2024.
Where is Elicio Therapeutics, Inc.'s common stock registered for trading?
Elicio Therapeutics, Inc.'s common stock, with the trading symbol ELTX, is registered on The Nasdaq Global Select Market.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-01-17 08:35:57
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Glo
Filing Documents
- angn-20240117.htm (8-K) — 23KB
- eliciotherapeutics_ascog.htm (EX-99.1) — 14KB
- eliciotherapeutics_ascog001.jpg (GRAPHIC) — 258KB
- eliciotherapeutics_ascog002.jpg (GRAPHIC) — 228KB
- eliciotherapeutics_ascog003.jpg (GRAPHIC) — 265KB
- eliciotherapeutics_ascog004.jpg (GRAPHIC) — 285KB
- eliciotherapeutics_ascog005.jpg (GRAPHIC) — 38KB
- 0001601485-24-000009.txt ( ) — 1650KB
- angn-20240117.xsd (EX-101.SCH) — 2KB
- angn-20240117_lab.xml (EX-101.LAB) — 25KB
- angn-20240117_pre.xml (EX-101.PRE) — 13KB
- angn-20240117_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 17, 2024, Elicio Therapeutics, Inc. (the "Company") issued a press release announcing a Trial in Progress poster presentation on the Phase 1/2 (AMPLIFY-7P) study design at the ASCO Gastrointestinal Cancers ("ASCO GI") Symposium being held January 18-20, 2024 in San Francisco, CA. The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma ("PDAC"). A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release of Elicio Therapeutics, Inc., dated January 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: January 17, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer)